Client Billings Customer was Interpace Biosciences’s largest revenue line in fiscal 2025, bringing in $13.13M of $38.49M (34%).
| Customer | FY 2017 | FY 2019 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Medicare Customer | $14.41M | $16.42M | $17.01M | $10.37M | ||
| Commercial Payers Customer | $7.15M | $9.53M | $10.78M | $10.55M | ||
| Client Billings Customer | $5.68M | $8.17M | $10.95M | $13.13M | ||
| Commercial Payors Customer | — | — | — | — | ||
| Medicare Advantage Customer | $4.38M | $5.61M | $7.56M | $4.45M | ||
| Total | $31.63M | $39.72M | $46.30M | $38.49M |
Interpace Biosciences brought in $38.49M from its four revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 16.9% from $46.30M in fiscal 2024. Client Billings Customer was the largest at $13.13M (34.1%), ahead of Commercial Payers Customer at $10.55M (27.4%) and Medicare Customer at $10.37M (26.9%). The remaining revenue line, Medicare Advantage Customer, brought in $4.45M.
Compared with fiscal 2024, Client Billings Customer grew fastest, up 19.9% to $13.13M, while Medicare Advantage Customer fell the most, down 41.1% to $4.45M. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $31.63M to $38.49M, a compound annual growth rate of 6.8%. Client Billings Customer's share of the total rose from 18.0% to 34.1%.
Previously Reported was Interpace Biosciences’s largest revenue line in fiscal 2024, bringing in $34.61M of $34.52M (100%).
| Revision of Prior Period | FY 2018 | FY 2023 | FY 2023 | FY 2023 | FY 2023 | FY 2024 | FY 2024 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| Previously Reported | $9.83M | $20.85M | $9.08M | $40.21M | $10.27M | $22.31M | $34.61M | |
| As Previously Reported | — | — | — | — | — | — | — | |
| Revision Of Prior Period, Reclassification, Adjustment | -$171.00K | $19.00K | $125.00K | -$178.00K | -$95.00K | -$95.00K | -$95.00K | |
| Total | $9.66M | $20.87M | $9.20M | $40.04M | $10.18M | $22.22M | $34.52M |
Interpace Biosciences brought in $34.52M from its two revenue lines in fiscal 2024, the year ended September 30, 2024. That was up 55.3% from $22.22M in fiscal 2024. Previously Reported was the largest at $34.61M (100.3%).
The total is net of Revision Of Prior Period, Reclassification, Adjustment, which took $95.00K off revenue in fiscal 2024.
Balances Without Adoption Of Asc 606 was Interpace Biosciences’s largest revenue line in fiscal 2018, bringing in $21.24M of $21.90M (97%).
| Scenario | FY 2018 |
|---|---|
| Balances Without Adoption Of Asc 606 | $21.24M |
| Effect Of Change Higher/(Lower) | $653.00K |
| Total | $21.90M |
Interpace Biosciences brought in $21.90M from its two revenue lines in fiscal 2018, the year ended December 31, 2018. Balances Without Adoption Of Asc 606 was the largest at $21.24M (97.0%), ahead of Effect Of Change Higher/(Lower) at $653.00K (3.0%).
Interpace Biosciences (IDXG) reports its revenue by customer, by revision of prior period and by scenario. In fiscal 2025, Client Billings Customer was its largest revenue line, bringing in $13.13M (34.1% of the total), followed by Commercial Payers Customer at $10.55M (27.4%).
Client Billings Customer was Interpace Biosciences' largest revenue line in fiscal 2025, bringing in $13.13M, or 34.1% of the $38.49M total across its four revenue lines.
Among Interpace Biosciences' revenue lines that make up at least 2% of revenue, Client Billings Customer grew fastest in fiscal 2025, up 19.9% from $10.95M to $13.13M.
Every figure comes from Interpace Biosciences' annual financial filings, as reported. Each line keeps the name Interpace Biosciences gives it, and years follow its fiscal calendar.
Interpace Biosciences' revenue by customer goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.